

Status: Currently Official on 16-Feb-2025

Official Date: Official as of 01-Dec-2024

Document Type: USP Monographs

DocId: GUID-3F24EFCC-FA7C-4984-AC05-39E8B7D7C128_3_en-US

DOI: https://doi.org/10.31003/USPNF_M58160_03_01

DOI Ref: 1j6hq

© 2025 USPC

Do not distribute

Nystatin, Neomycin Sulfate, Gramicidin, and Triamcinolone Acetonide Cream

DEFINITION

Nystatin, Neomycin Sulfate, Gramicidin, and Triamcinolone Acetonide Cream contains NLT 90.0% and NMT 140.0% of the labeled amounts of nystatin, neomycin, and gramicidin, and NLT 90.0% and NMT 110.0% of the labeled amount of triamcinolone acetonide ($C_{24}H_{31}FO_6$).

IDENTIFICATION

• A. THIN-LAYER CHROMATOGRAPHY

Standard solution: 100 µg/mL of [USP Triamcinolone Acetonide RS](#) in [chloroform](#)

Sample solution: Transfer 2 g of Cream into a conical flask, add 5.0 mL of [chloroform](#), and shake for 10 min. Add 15 mL of [alcohol](#), and shake for an additional 10 min. Filter the solution into a centrifuge tube, and evaporate the filtrate to dryness. Dissolve the residue in [alcohol](#) to obtain a solution containing about 250 µg/mL of triamcinolone acetonide.

Chromatographic system

(See [Chromatography \(621\), General Procedures, Thin-Layer Chromatography](#).)

Mode: TLC

Adsorbent: 0.25-mm layer of chromatographic silica gel

Application volume: 10 µL

Developing solvent system: [Chloroform](#), [benzene](#), and [methanol](#) (5:2:1)

Spray reagent: A mixture of a 1-in-5 solution of [sodium hydroxide](#) and a 1-in-500 solution of [blue tetrazolium](#) in [methanol](#) (1:1)

Analysis

Samples: Standard solution and Sample solution

Apply the Standard solution and the Sample solution on a line parallel to and about 1.5 cm from the bottom edge of the TLC plate. Proceed as directed in the chapter and develop in the Developing solvent system until the solvent front has moved about 12 cm above the application line. Remove the plate, allow the solvent to evaporate, and spray with Spray reagent.

Acceptance criteria: The intensity of the blue color and the R_F of the spot of the Sample solution corresponds to that of the Standard solution.

ASSAY

• NYSTATIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Standard: [USP Nystatin RS](#)

Sample stock solution: Transfer a suitable, accurately weighed portion of Cream into a blender jar. Add a sufficient, accurately measured volume of [dimethylformamide](#) and blend at high speed for 3–5 min to obtain a convenient concentration. Dilute quantitatively an accurately measured volume of the solution so obtained with [dimethylformamide](#) to obtain a stock solution containing about 400 USP Nystatin Units/mL.

Sample solution: Dilute an accurately measured volume of the Sample stock solution quantitatively with [Buffer B.6](#) to obtain a nominal concentration of nystatin equal to the median concentration of the Standard.

Analysis: Proceed as directed for nystatin in the chapter.

Acceptance criteria: 90.0%–140.0% of the labeled amount of nystatin

• NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Standard: [USP Neomycin Sulfate RS](#)

Sample stock solution: Transfer an accurately weighed portion of Cream, equivalent to about 1.75 mg of neomycin, to a separator, add about 50 mL of [ether](#), and shake well. Extract with four 20-mL portions of [Buffer B.3](#). Combine the aqueous extracts, and dilute with [Buffer B.3](#) to an appropriate volume to obtain a stock solution of convenient concentration.

Sample solution: Dilute the *Sample stock solution* quantitatively and stepwise with *Buffer B.3* to obtain a nominal concentration of neomycin equal to the median concentration of the *Standard*.

Analysis: Proceed as directed for neomycin in the chapter.

Acceptance criteria: 90.0%–140.0% of the labeled amount of neomycin

• **GRAMICIDIN**

(See [Antibiotics—Microbial Assays \(81\)](#).)

Standard: [USP Gramicidin RS](#)

Sample stock solution: Dissolve an accurately weighed portion of Cream in 50 mL of [hexanes](#), transfer into a separator, and extract with four 20-mL portions of 80% [alcohol](#). Combine the extracts in a suitable volumetric flask, dilute with [alcohol](#) to volume, and mix.

Sample solution: Dilute an accurately measured volume of the *Sample stock solution* quantitatively and stepwise with [alcohol](#) to obtain a nominal concentration of gramicidin equal to the median concentration of the *Standard*.

Analysis: Proceed as directed for gramicidin in the chapter.

Acceptance criteria: 90.0%–140.0% of the labeled amount of gramicidin

Change to read:

• **TRIAMCINOLONE ACETONIDE**

Mobile phase: [Acetonitrile](#) and [water](#) (approximately 30:70)

Internal standard solution: 50 µg/mL of fluoxymesterone in [isopropyl alcohol](#)

Standard stock solution: 75 µg/mL of [USP Triamcinolone Acetonide RS](#) in the *Internal standard solution*

Standard solution: Mix an accurately measured volume of the *Standard stock solution* with an equal volume of *Mobile phase* to obtain a solution containing about 37.5 µg/mL of [USP Triamcinolone Acetonide RS](#).

Sample solution: Transfer an accurately weighed quantity of Cream, equivalent to about 1.5 mg of triamcinolone acetonide, to a screw-capped tube. Add 20.0 mL of the *Internal standard solution*, and cap securely. Heat at 60° for 5 min, and then swirl vigorously for NLT 30 s. Repeat the heating and swirling sequence 3 times. Cool in a methanol-ice bath for 15–20 min, and then centrifuge at –5° for 15 min. Dilute an accurately measured volume of the supernatant with an equal volume of *Mobile phase*. Cool in a methanol-ice bath for 10–15 min, with occasional agitation. Pass first through a pledge of glass wool or a prefilter disk, and then pass through a membrane of 0.45-µm pore size to obtain a clear solution.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

[**NOTE**—Adjust the operating parameters with *Mobile phase*, such that the separation of triamcinolone acetonide and the internal standard is optimized, with a retention time of about 14.5 min for triamcinolone acetonide.]

Mode: LC

Detector: UV 254 nm

Column: 4-mm × 30-cm; packing [L1](#)

Column temperature: Room temperature

Injection volume: 15–25 µL of equal volumes of the *Standard solution* and *Sample solution*

System suitability

Sample: *Standard solution*

Suitability requirements

Resolution: NLT 2.0 between the triamcinolone acetonide and fluoxymesterone peaks

Relative standard deviation: NMT 3.0% for 5 replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Measure the peak heights of the internal standard and triamcinolone acetonide at the same retention times obtained from the *Standard solution* and *Sample solution*.

▲ Calculate the percentage of the labeled amount of triamcinolone acetonide ($C_{24}H_{31}FO_6$) in the portion of Cream taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

R_U = peak height ratio of triamcinolone acetonide to the internal standard from the *Sample solution*

R_S = peak height ratio of triamcinolone acetonide to the internal standard from the *Standard solution*

C_S = concentration of [USP Triamcinolone Acetonide RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of triamcinolone acetonide in the *Sample solution* (mg/mL)

▲ (USP 1-Dec-2024)

Acceptance criteria: 90.0%–110.0%**SPECIFIC TESTS**

- [MINIMUM FILL \(755\)](#): Meets the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.

- [USP REFERENCE STANDARDS \(11\)](#):

[USP Gramicidin RS](#)[USP Neomycin Sulfate RS](#)[USP Nystatin RS](#)[USP Triamcinolone Acetonide RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NYSTATIN, NEOMYCIN SULFATE, GRAMICIDIN, AND TRIAMCINOLONE ACETONIDE CREAM	Ying Han Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 49(4)

Current DocID: GUID-3F24EFCC-FA7C-4984-AC05-39E8B7D7C128_3_en-US**DOI: https://doi.org/10.31003/USPNF_M58160_03_01****DOI ref: [1j6hq](#)**